anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention refers to medicine.         Technical result of the invention is the increase of productivity of process. The acidified solution of interferon is passed through a column with cross-linked dextrane. Interferon is eluated by the phosphatic buffer. The part of the eluent is passed through a column with metalchelating carrier. Then interferon is eluated by a solution of histidine with sodium chloride. The obtained eluent contains the slight quantity of pyrogenic substances meeting the requirements for biological substances.          2 tables
Voltage-gated potassium channel 1.3 (Kv1.3) has emerged as a pivotal player in numerous biological processes and pathological conditions, sparking considerable interest as a potential therapeutic target across various diseases. In this review, we present a comprehensive examination of Kv1.3 channels, highlighting their fundamental characteristics and recent advancements in utilizing Kv1.3 inhibitors for treating autoimmune disorders, neuroinflammation, and cancers. Notably, Kv1.3 is prominently expressed in immune cells and implicated in immune responses and inflammation associated with autoimmune diseases and chronic inflammatory conditions. Moreover, its aberrant expression in certain tumors underscores its role in cancer progression. While preclinical studies have demonstrated the efficacy of Kv1.3 inhibitors, their clinical translation remains pending. Molecular imaging techniques offer promising avenues for tracking Kv1.3 inhibitors and assessing their therapeutic efficacy, thereby facilitating their development and clinical application. Challenges and future directions in Kv1.3 inhibitor research are also discussed, emphasizing the significant potential of targeting Kv1.3 as a promising therapeutic strategy across a spectrum of diseases.
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
There is great interest in developing clinical biomarker assays that can aid in non-invasive diagnosis and/or monitoring of human diseases, such as cancer, cardiovascular disease, and neurological diseases. Yet little is known about the longitudinal stability of miRNAs in human plasma. Here we assessed the intraindividual longitudinal stability of miRNAs in plasma from healthy human adults, and the impact of common factors (e.g., hemolysis, age) that may confound miRNA data. We collected blood by venipuncture biweekly over a 3-month period from 22 research participants who had fasted overnight, isolated total RNA, then performed miRNA qPCR. Filtering and normalization of the qPCR data revealed amplification of 134 miRNAs, 74 of which had high test-retest reliability and low percentage level drift, meaning they were stable in an individual over the 3-month time period. We also determined that, of nuisance factors, hemolysis and tobacco use have the greatest impact on miRNA levels and variance. These findings support that many miRNAs show intraindividual longitudinal stability in plasma from healthy human adults, including some reported as candidate biomarkers for Alzheimer's disease.
The present invention discloses a capsule curing cold and cough, a preparation method thereof and a detection method thereof. The capsule is composed of bupleurum root, kudzuvine root, platycodon root, bitter apricot seed, weeping forsythia capsule, baical skullcap root, sweet wormwood herb, honeysuckle flower, menthol, beta-cyclodextrin and magnesium stearate. Except for the menthol, the other 8 medicines are respectively decocted with water twice for 4 hours; the decoction solutions are merged and filtered, and the filter solution is concentrated into an extract under reduced pressure; 80% of the extract is taken to be treated through spray drying, and spray power is prepared; the menthol is prepared into an ethanol solution of 10%, and is treated with a saturated solution of the beta-cyclodextrin for inclusion; the stirring speed is 300 revolutions per minute, and the inclusion lasts for 2 hours. The solution is put in a refrigerator for 24 hours, is filtered and is dried at 40 DEG C, and an inclusion compound is prepared. The inclusion compound is mixed with the spray powder with an equivalent incremental method; then the mixture and the rest 20% of the extract are treated through boiling granulating; the granules are pulverized, dried, added with and mixed the magnesium stearate, and filled in a capsule. The detection method comprises: a high performance liquid chromatography method is used to measure the content of puerarin in the capsule curing cold and cough. The capsule has good curative effect, no toxic or side effect, safe and convenient taking.
The PREPARE trial is a prospective, randomized trial conducted with the aim to determine non-inferiority of the primary outcome between POPQ-based surgery and simulated apical support-based surgery for anterior or posterior vaginal wall prolapse. Participants will undergo transvaginal surgery for prolapse, including the assigned procedure for anterior or posterior vaginal prolapse under general or spinal anesthesia. Concomitant procedures will be performed as intended prior to surgery. Women with a uterus in situ will undergo hysterectomy and all women will receive transvaginal vault suspension, including uterosacral ligament suspension, sacrospinous ligament fixation, and iliococcygeal suspension with both delayed absorbable and permanent sutures, according to the preference of surgeon. Incontinence surgery will also be performed for women with documented urodynamic stress incontinence.

A standardized protocol for enrollment, treatment and data collection will be employed by all sites. The study will be a single-blind study, as it is impossible to blind the study surgeon for the surgical procedure to which the subject in assigned. However, it is our intent that when feasible and ethical, all outcomes assessors and the subjects will be blinded to the treatment assignment. Postoperative follow-up will take place after 5 weeks and 6, 12, and 24 months. Patients will undergo a standard gynecological examination including POPQ and fill in questionnaires.
Arthritis is an inflammation of one or more joints, characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. There are many different forms of arthritis. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. In some patients, it is caused by injury or congenital abnormalities in the proteins that make up cartilage. Generally, it seems that aging, an unbalanced diet, and an inappropriate lifestyle are the causes of this disease.

Once the cartilage tissue changes from smooth to rough or breaks into small pieces, the cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that bear weight, such as the spine, knees, hips, and back. It is usually preceded by pain and symptoms of stiffness (often stiffness first, then pain), but swelling is not always present. In a small number of cases, osteoarthritis can cause disability. As the condition progresses, the bones can become more fragmented, increasing the likelihood of fractures. When osteoarthritis is more severe, bones can overgrow into osteophytes, known as bone spurs. These bone spurs can be detected with X-rays, usually near degenerative cartilage in the neck or waist. However, these changes typically do not alter the appearance of the affected area.

There are more than 28 types of peptides that make up collagen, with the more common types I, II, and III collagen accounting for about 90% of the total. Type II collagen forms joints. When collagen from pork bones and other sources is cooked at high temperatures, the collagen structure is destroyed, becoming denatured collagen. Additional supplements can only be used as general collagen and, therefore, cannot reduce the damage and inflammation of joint cartilage. Many studies have confirmed that the use of 'non-denatured type II collagen' (UC-II) can provide flexible maintenance for key parts. To achieve higher efficiency and longer-lasting effects, it is combined with glucosamine, chondroitin, and curcumin. In addition to providing resistance to compression in articular cartilage, it can also improve inflammation and significantly reduce pain in patients with primary osteoarthritis. Therefore, this research evaluated the effects of UCII, glucosamine and curcumin supplementation on knee pain and inflammation.
Robotic esophagectomy has improved early outcomes and enhanced the quality of lymphadenectomy for esophageal cancer surgery. This study aimed to determine risk factors for long-term survival following robotic esophagectomy and the causes of long-term mortality. We included patients who underwent robotic esophagectomy at our institute between 2010 and 2022. Robotic esophagectomy was defined as a surgical procedure performed robotically in both the abdomen and thorax. Robotic esophagectomy was performed in patients at all stages, including advanced stages, even in patients with stage IV and supraclavicular lymph node metastasis. A total of 340 patients underwent robotic esophagectomy during the study period. Ivor-Lewis operation and McKeown operation were performed on 153 (45.0%) and 187 (55.0%) patients, respectively. The five-year survival rates based on clinical stages were as follows: 85.2% in stage I, 62.0% in stage II, 54.5% in stage III, and 40.3% in stage IV. Risk factors for long-term survival included body mass index, Charlson comorbidity index, clinical stages, and postoperative complications of grade 4 or higher. Among the cases of long-term mortality, recurrence accounted for 42 patients (61.7%), while non-cancer-related death occurred in 26 patients (38.2%). The most common cause of non-cancer-related death was malnutrition and poor general condition, observed in 11 patients (16.2%). Robotic esophagectomy has demonstrated the ability to achieve acceptable long-term survival rates, even in patients with cervical lymph node metastasis. However, addressing high-grade postoperative complications and long-term malnutrition remains crucial for further improving the long-term survival outcomes of patients with esophageal cancer.
FIELD: chemical industry. SUBSTANCE: process for preparing 1,2,3,4-tetrahydro-2-methyl-1,4-dioxonaphalene- 2-sulfoacid sodium salt (vicasol) comprises reacting 2- methyl-1,4-napthoquinone (menadione) with sodium bisulfite (NaHSO 3 ) aqueous solution. Reaction is carried out in two-phase system consisting of aqueous phase and incombustible organic solvent. Aqueous phase is essentially sodium bisulfite solution having concentration from 4 to 6.5 mole/l, and organic phase is menadione solution. Reaction is carried out at temperature of not higher than 40 C. These conditions simplify and make cheaper technology of regeneration of organic solvents and also method of purification and recovery of vicasol. The resulting product comprises 0.5-2 wt % Na 2 S 2 O 5  which stabilizes vicasol and maintains its proper storage and light resistance. EFFECT: more efficient preparation process. 5 cl
The present invention provides a semipermeable membrane oral dosage form of ticagrelor comprising a core and a clad core. The core includes a first drug-containing layer and a push layer. The first drug-containing layer comprises the active drug ticagrelor in an amount sufficient to deliver an effective dose over the expected delivery time. The push layer includes a swelling agent and an osmotic agent. The semipermeable membrane has at least one passageway therethrough configured to be on the side of the first drug-containing layer in the core other than the push layer, the passageway being functionally configured to allow extended release of ticagrelor from the first drug-containing layer in the core when the dosage form is in an aqueous environment. The dosage form optionally further comprises a second ticagrelor-containing layer that surrounds the semipermeable membrane to provide an initial effective dose upon administration. The dosage form enables administration of ticagrelor once daily to a patient in need thereof.
Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
Technologies for a patient care exchange portal with market analysis include a care exchange server and one or more care provider devices and care coordinator devices. The care exchange server registers multiple care providers and configures provider profiles. The care exchange server receives a care coordinator request and selects one or more care providers that match the request. The matching care providers are notified and may respond with interest to the request. The care coordinator and/or an individual patient may review the interested care providers and accept a care provider. The care exchange server may provide a personalized exchange view to the individual. The care exchange server may generate business intelligence and market analysis for a care provider. Other embodiments are described and claimed.
The invention belongs to the field of medicines, and concretely relates to a diarrhea treatment medicine. The diarrhea treatment medicine comprises 25g of Radix Codonopsis, 25g of Rhizoma Atractylodis Macrocephalae, 25g of dried orange peel, 15g of Fructus Aurantii, 15g of Pinellia Tuber, 15g of Radix Platycodonis, 20g of Fructus Evodiae, 20g of Malaytea Scurfpea Fruit, 10g of Chinese magnoliavine and 20g of Poria cocos. The medicine is prepared through the following steps: mixing the above medicines, rapidly flushing, immersing for 2h, boiling for 30min three times, filtering, concentrating the obtained filtrate, and processing through a routine traditional Chinese medicinal preparation method to prepare particles. The medicine is taken according to a medicine/raw medicines ratio of 1g/kg three times every day. The medicine is used for treating diarrhea, and has the efficacies of spleen invigorating, dampness disinhibiting, middle warmer warming and diarrhea stopping. The medicine is used to clinically treat 30 patients, 27 patients are cured, and the result of one patient is not fed back.
The following adverse reactions have been identified during postapproval use of sumatriptan succinate tablets, sumatriptan nasal spray, and sumatriptan injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to sumatriptan succinate or a combination of these factors.

: Hypotension, palpitations. Cardiovascular

: Dystonia, tremor. Neurological
PURPOSE: To obtain the subject new compound useful as a therapeutic agent for arteriosclerosis, cardiac infarction, etc., by preventing low density lipoprotein(LDL) from being oxidatively denatured. CONSTITUTION: A compound of formula I [R1 is H, a (substituted)straight-chain or branched chainlike 1-2OC alkyl, a (substituted)alkylcarbonyl, etc.; R2 and R3 are each H, a (substituted)straight chain or branched chainlike 2-20C alkenyl, etc.], e.g. 5,7-di-t-butyl-2,2-dimethyl-6-hydroxy-2H-3,4-dihydrobenzo[b]pyran. The compound of formula I is obtained by reacting a compound of formula II with acetic anhydride in the presence of an alkali metallic salt of acetic acid, forming the coumarin skeleton of formula III, then carrying out the Grignard reaction of the resultant compound of formula III, providing a compound of formula IV which is a new synthetic intermediate for the compound of formula I and then reducing the double bond. A compound of formula V is cited as the new synthetic intermediate.
Following the pretest, "genital hygiene behaviors training" was provided to the women in the intervention group by E.S.B., one the researchers. In addition, a genital hygiene brochure prepared by the researchers which included the same content as the training was given to each participant. The training program was carried out as oral instruction as well as using the demonstration method which is called as "tell-show-do". Individual questions of the women were answered at the end of the training. In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Four weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method. Four weeks after the data collection tools used in the research were filled in as a pre-test, post-test data were obtained with the same measurement tools.
In the last few years, a new clinical entity has emerged which includes patients who consider themselves to be suffering from problems caused by wheat and/or gluten ingestion, even though they do not have celiac disease (CD) or wheat allergy. This clinical condition has been named non-celiac gluten sensitivity (NCGS), although in a recent article, the researchers suggested the term "non-celiac wheat sensitivity" (NCWS), because it is not known to date what component of wheat actually causes the symptoms. Other areas of doubt in NCWS regard its pathogenesis, while some papers reported intestinal immunologic activation, others linked NCWS to the dietary short chain carbohydrate (fermentable oligo-di-monosaccharides and polyols, FODMAPs) load. The researchers recently demonstrated that higher proportions of patients with NCWS develop autoimmune disorders, are antinuclear antibodies (ANA) positive, and show DQ2/DQ8 haplotypes compared with patients with irritable bowel syndrome (IBS), supporting an immunologic involvement in NCWS. The clinical picture of NCWS is characterized by combined gastrointestinal (bloating, abdominal pain, diarrhea and/or constipation, nausea, epigastric pain, gastroesophageal reflux, aphthous stomatitis) and extra-intestinal or systemic manifestations (headache, depression, anxiety, 'foggy mind,' tiredness, dermatitis or skin rash, fibromyalgia-like joint/muscle pain, leg or arm numbness, and anemia). Lactose intolerance and cow's milk protein allergy (CMPA) are two conditions with a very high prevalence in the general population and there is a large overlap between NCWS and lactose intolerance and CMPA symptoms. Therefore, the aims of the present study are to investigate 1) the prevalence of positive lactose breath test and DBPC cow's milk protein challenge in NCWS patients with self-reported gastrointestinal and extra-intestinal symptoms related to milk and/or milk derivates ingestion, 2) the clinical, serological, and histological characteristics of NCWS patients with lactose intolerance and CMPA in comparison to NCWS patients without lactose intolerance and CMPA.
The invention relates to coating of suppositories containing free unsaturated fatty acid, fatty acid ethyl ester and fatty acid monoglyceride that are susceptible to oxidative degradation. The coating retards oxidative degradation of unsaturated fatty acids and gives the suppository a non-oily and smooth surface. The coating will enhance the shelf-life of the suppository and allow their storage at room temperature for extended time period. The coating may or may not contain medicament such as local anesthetic or steroid. According to this invention chemically unstable fatty acids in coated suppositories can be used to stimulate the process of defecation or to treat disorders such as hemorrhoids, bacterial infections, viral infections and inflammations, as well as against fissura ani and pruritus ani. Furthermore, coating suppositories, that contain high concentrations of free fatty acids, can reduce acid induced rectal irritation.
A composition for use in a method of detecting cancer comprising a plurality of DNA molecules comprising a plurality of different cancer-activated/cancer-specific promoters linked to reporter proteins, wherein the promoters drive expression of the reporter proteins in a cancer cell, wherein the DNA molecules are plasmids, minicircles, nanoplasmids, or linear vectors, and a pharmaceutically acceptable carrier. The composition may be administered intravenously for non-invasive imaging, such as MRI, PET, SPECT, photoacoustic, or luminescence imaging. The cancer-activated promoter may be, for example, a Survivin promoter (BIRC5), CXCR4, ABCC4, AGR2 etc. The composition may further comprise a transfection agent, such as a nanoparticle. The reporter protein may be a luciferase, a green fluorescent protein (GFP), a red fluorescent protein (RFP), horseradish peroxidase (HRP), an alkaline phosphatase (AP, SEAP) or glucose oxidase (GO). The nanoplasmids may comprise a minimised bacterial ColE1 or R6K origin of replication and a selectable marker. Also claimed is a composition for detecting cancer in a blood sample, wherein the composition comprises multiple DNA molecules comprising a plurality of/multiple promoters specific to cancer operably linked to reporter proteins. Transfection of the multiplex promoter into tumour cells drives expression of cancer-activated genes for diagnosing cancer.
This study aims to learn more about the subset of children with Eosinophilic Esophagitis (EoE) who are on treatment with a proton pump inhibitor (PPI). EoE is an increasingly common allergic condition of the esophagus for which we have limited treatment options. This study will be helpful in evaluating the minimal time frame required for histological improvement with the use of high dose PPI. The study will enroll participants who have been diagnosed with Eosinophilic Esophagitis (EoE) and are recommended by their physician to begin PPI treatment with Omeprazole 20 mg twice daily. After taking Omeprazole for four weeks, the participant will undergo an unsedated Transnasal Endoscopy (TNE) in the outpatient clinic at Children's Hospital Colorado. TNE is a test in which the doctor inserts a skinny bendable tube with a camera through the nose to look directly into the esophagus (the tube connecting the mouth to the stomach when you swallow) and is an alternative method to assess esophageal mucosa without requiring general anesthesia. Biopsies will be collected during the TNE to determine if there is histological change. If the biopsies are normal, the participant will complete the study. If biopsies are abnormal, and EoE is still active, the participant will continue the Omeprazole and undergo the standard of care endoscopy at eight weeks. The participant will choose the type of endoscopy- unsedated TNE or esophagogastroduodenoscopy (EGD) under anesthesia. Participants will also complete surveys during study enrollment about medication compliance, Eosinophilic Esophagitis symptoms, anxiety, TNE experience, and undergo a physical exam. The investigators hypothesize that following the initiation of PPI for treatment of Eosinophilic Esophagitis, biopsies obtained will show decreasing eosinophil counts at four weeks, which is sooner than the previously reported eight-week period. Results from this study will be generalizable to the pediatric EoE population and the knowledge gained will provide key preliminary data to support clinical recommendations for pediatric EoE patients.